secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001493152-24-038339
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs director Eleanor McBrier resigns; Nasdaq audit committee vacancy triggers non-compliance cure period
--------------------------------------------------------------------------------

- Eleanor McBrier resigned as director effective Sep 20, 2024 due to conflict with employer policies; no dispute with company.
- Vacancy on audit committee caused non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).
- Nasdaq confirmed non-compliance on Sep 26; cure period ends earlier of next annual meeting or Sep 20, 2025.
- Company plans to regain compliance and is searching for a replacement with gastroenterology focus for BE-Smart test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315224038339/0001493152-24-038339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315224038339/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-038339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer